Treatment of Familial Hypercholesterolemia in Children and Adolescents: Effect of Lovastatin
The DOI matches its Crossref record.
Abstract
Objective. Familial hypercholesterolemia (FH), an inherited autosomal dominant disorder of lipoprotein metabolism, is associated with premature atherosclerosis. The recommended pediatric therapy consists of dietary intervention and, when necessary, treatment with bile acid-binding resins. However, compliance has been poor in many children. Therefore, our objectives were to determine the efficacy, safety, and tolerance of the short-term use of lovastatin, a 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitor, in the control of severe FH in a male pediatric population and to evaluate the dose-response relationship. Methods. Sixty-nine male patients with FH 12.9 ± 2.4 years of age (mean ± SD) participated in this multicenter, randomized, double-blind trial. After a 4-week placebo period, the patients were allocated to four treatment groups (lovastatin 10, 20, 30, or 40 mg/d) for 8 weeks. Plasma lipid and apolipoprotein (Apo) concentrations were measured every 2 weeks. Clinical and laboratory evidence of adverse events was monitored periodically throughout the study. Results. All lovastatin doses reduced total cholesterol (—17% to —29%), low-density lipoprotein cholesterol (—21% to —36%), and ApoB (—19% to —28%) concentrations. A dose-response relationship was seen, and between-group comparisons showed that results were significantly improved up to a dose of 30 mg/d. We observed a 7% increase in high-density lipoprotein cholesterol and a 4% increase in ApoA1 concentrations. The medication was well tolerated by all patients. No serious clinical adverse experience was reported. Lovastatin increased aspartate aminotransferase concentrations, but there was no evidence of a dose-response relationship, and no value exceeded two times the upper limit of normal. No significant change in alanine aminotransferase was observed. Three patients had marked (more than three times the upper limit of normal) asymptomatic elevations in their creatine kinase values, which returned spontaneously to normal, and no action was required regarding the drug. Conclusions. Lovastatin is an effective therapy for severe FH in children and adolescents. It was well tolerated, and the occurrence of adverse experiences of clinical significance was very low. Long-term pediatric studies are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis
Robin DiMatteo, M., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002) · Medical Care · doi:10.1097/00005650-200209000-00009 · Cited by 1,490
Lipid screening and cardiovascular health in childhood
Daniels, S. R., Greer, F. R., & and the Committee on Nutrition (2008) · Pediatrics · doi:10.1542/peds.2008-1349 · Cited by 1,178
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Kavey, R.-E. W., Allada, V., Daniels, S. R., Hayman, L. L., McCrindle, B. W., Newburger, J. W., Parekh, R. S., & Steinberger, J. (2006) · Circulation · doi:10.1161/circulationaha.106.179568 · Cited by 707
Wiegman, A., Hutten, B. A., de Groot, E., Rodenburg, J., Bakker, H. D., Büller, H. R., Sijbrands, E. J. G., & Kastelein, J. J. P. (2004) · JAMA · doi:10.1001/jama.292.3.331 · Cited by 649
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
McCrindle, B. W., Urbina, E. M., Dennison, B. A., Jacobson, M. S., Steinberger, J., Rocchini, A. P., Hayman, L. L., & Daniels, S. R. (2007) · Circulation · doi:10.1161/circulationaha.107.181946 · Cited by 418
Early statin therapy restores endothelial function in children with familial hypercholesterolemia
de Jongh, S., Lilien, M. R., op’t Roodt, J., Stroes, E. S. G., Bakker, H. D., & Kastelein, J. J. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02593-7 · Cited by 367
Kasiske, B., Cosio, F. G., Beto, J., Bolton, K., Chavers, B. M., Grimm, R., Levin, A., Masri, B., Parekh, R., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 316
de Jongh, S., Ose, L., Szamosi, T., Gagné, C., Lambert, M., Scott, R., Perron, P., Dobbelaere, D., Saborio, M., Tuohy, M. B., et al. (2002) · Circulation · doi:10.1161/01.cir.0000035247.42888.82 · Cited by 308
Self-citationOkamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Compliance with cardiovascular disease prevention strategies: A review of the research
Burke, L. E., Dunbar-Jacob, J. M., & Hill, M. N. (1997) · Annals of Behavioral Medicine · doi:10.1007/bf02892289 · Cited by 286
Stein, E. A., Illingworth, D. R., Kwiterovich, Jr., Liacouras, C. A., Siimes, M. A., Jacobson, M. S., Brewster, T. G., Hopkins, P., Davidson, M., Graham, K., et al. (1999) · JAMA · doi:10.1001/jama.281.2.137 · Cited by 270
McCrindle, B. W., Ose, L., & Marais, A. D. (2003) · The Journal of Pediatrics · doi:10.1016/s0022-3476(03)00186-0 · Cited by 269
Statins for children with familial hypercholesterolemia
Vuorio, A., Kuoppala, J., Kovanen, P. T., Humphries, S. E., Tonstad, S., Wiegman, A., Drogari, E., & Ramaswami, U. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006401.pub4 · Cited by 265
Osterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230
“For human use, lovastatin is administered as a prodrug in its lactone form, which is metabolized into an active conformation (lovastatin acid) (Lambert et al., 1996).”
Daniels, S. R., Gidding, S. S., & de Ferranti, S. D. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.03.453 · Cited by 172
Asiminas, A., Jackson, A. D., Louros, S. R., Till, S. M., Spano, T., Dando, O., Bear, M. F., Chattarji, S., Hardingham, G. E., Osterweil, E. K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0498 · Cited by 78
Effect of lovastatin on behavior in children and adults with fragile X syndrome: An open‐label study
Çaku, A., Pellerin, D., Bouvier, P., Riou, E., & Corbin, F. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36750 · Cited by 77
“have demonstrated a good safety profile in this population [Lambert et al., 1996; Stein et al., 1999; Clauss et al., 2005].”
Background
Metadata
- Authors
- Lambert, M., Lupien, P.-J., Gagné, C., Lévy, E., Blaichman, S., Langlois, S., Hayden, M., Rose, V., Clarke, J. T. R., Wolfe, B. M. J., Clarson, C., Parsons, H., Stephure, D. K., Potvin, D., Lambert, J., & Canadian Lovastatin in Children Study Group
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 1996-05-01
- Volume
- 97
- Issue
- 5
- Pages
- 619-628
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W1934245552
- Cited by
- 157
- References
- 0
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.